title: Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".
authors.affiliation: Los Angeles Department of Health Services, CA 90012, USA. mhkatz59@yahoo.com
authors.forename: Mitchell H
authors.initials: MH
authors.lastname: Katz
mesh_terms: D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003718:Denmark / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006620:Hip Fractures / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D012306:Risk
chemical_list: D050071:Bone Density Conservation Agents; D054328:Proton Pump Inhibitors; D019386:Alendronate